Optimal designs for population pharmacokinetic studies of oral artesunate in patients with uncomplicated falciparum malaria by Jamsen, Kris M et al.
METHODOLOGY Open Access
Optimal designs for population pharmacokinetic
studies of oral artesunate in patients with
uncomplicated falciparum malaria
Kris M Jamsen
1*, Stephen B Duffull
2, Joel Tarning
3,4, Niklas Lindegardh
3,4, Nicholas J White
3,4 and Julie A Simpson
1
Abstract
Background: Currently, population pharmacokinetic (PK) studies of anti-malarial drugs are designed primarily by
the logistical and ethical constraints of taking blood samples from patients, and the statistical models that are
fitted to the data are not formally considered. This could lead to imprecise estimates of the target PK parameters,
and/or designs insufficient to estimate all of the parameters. Optimal design methodology has been developed to
determine blood sampling schedules that will yield precise parameter estimates within the practical constraints of
sampling the study populations. In this work optimal design methods were used to determine sampling designs
for typical future population PK studies of dihydroartemisinin, the principal biologically active metabolite of oral
artesunate.
Methods: Optimal designs were derived using freely available software and were based on appropriate structural
PK models from an analysis of data or the literature and key sampling constraints identified in a questionnaire sent
to active malaria researchers (3-4 samples per patient, at least 15 minutes between samples). The derived optimal
designs were then evaluated via simulation-estimation.
Results: The derived optimal sampling windows were 17 to 29 minutes, 30 to 57 minutes, 2.5 to 3.7 hours and 5.8
to 6.6 hours for non-pregnant adults; 16 to 29 minutes, 31 minutes to 1 hour, 2.0 to 3.4 hours and 5.5 to 6.6 hours
for designs with non-pregnant adults and children and 35 to 59 minutes, 1.2 to 3.4 hours, 3.4 to 4.9 hours and 6.0
to 8.0 hours for pregnant women. The optimal designs resulted in acceptable precision of the PK parameters.
Conclusions: The proposed sampling designs in this paper are robust and efficient and should be considered in
future PK studies of oral artesunate where only three or four blood samples can be collected.
Background
The World Health Organization recommends artemisi-
nin-based combination therapy (ACT) as first line treat-
ment for uncomplicated falciparum malaria in all
malaria endemic areas [1]. ACT involves treatment with
two or more different anti-malarial drugs - a highly
effective but short-lived artemisinin derivative, and a
less potent but longer-lived partner drug(s). Most anti-
malarial drugs were introduced with incomplete dose-
finding studies, so the dosage, particularly in some
important patient groups is too low. This is especially
true for young children and pregnant women, who carry
much of the malaria burden and are at greatest risk of
treatment failure [2].
To treat malaria effectively, the dose and frequency of
administration of the anti-malarial drug need to provide
drug concentrations over time sufficient to kill all of the
parasites in the body. This drug concentration-time pro-
file is determined by the pharmacokinetic (PK) proper-
ties of the drug [3]. Previous studies have shown that
anti-malarial pharmacokinetics for children and preg-
nant women can differ substantially from non-pregnant
adults given the same dosing regimen [4,5]. Therefore,
there is an urgent need to characterise the concentra-
tion-time profile in vulnerable patient groups so that
optimal dosing regimens can be determined.
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plicated malaria the invasiveness of taking many blood
samples is not acceptable to the patient or parent. Thus
the intensive blood sampling that would make for ideal
population PK modeling is not feasible, so the times at
which the blood samples are taken must be chosen care-
fully so that information is maximised and the PK para-
meters can be estimated with reasonable precision. This
requires knowledge of the structural PK model for the
drug(s) being studied and formal consideration of how
the population PK model is fitted to the data. Given
that there is such limited opportunity to take blood
samples, failing to consider the statistical techniques
required to estimate the target parameters can lead to
designs that are inefficient (provide imprecise estimates
of model parameters) and in some cases study failure.
This wastes time and money and is arguably unethical
since volunteers participating in these studies have con-
tributed their time, discomfort and biological samples
needlessly. Hence there is a scientific and ethical incen-
tive to design population pharmacokinetic studies so
that precise parameter estimation is achievable [3].
The theory of optimal design has been developed to
propose the ideal timing of blood sampling when design-
ing population PK studies [6]. Optimal design methods
incorporate knowledge of the PK profile of the drug, the
practical constraints of blood sampling and the statistical
techniques used to estimate the PK parameters. The
resulting optimal design yields the lowest possible values
of the standard errors of the estimated PK parameters
from within the practical constraints of sampling
patients. To date, this methodology has not been applied
to population PK studies of anti-malarial drugs. Previous
works in other areas have concentrated on providing a
case specific design (e.g. Waterhouse et al. [7]), whereas
the intention of this work is to provide designs that can
be applied to a wide range of future studies.
This investigation focuses on dihydroartemisinin
(DHA) following oral administration of artesunate (AS),
the main artemisinin derivative used to treat uncompli-
cated falciparum malaria. AS is rapidly hydrolysed to
DHA, its principal biologically active metabolite. Most
of the anti-malarial activity of artesunate is explained by
DHA. These class of drugs reduce the number of para-
sites in the body faster than any other anti-malarial
drugs [8]. Oral AS is rapidly absorbed and eliminated
from the body, providing about 6-8 hours to take blood
samples post-dosing.
The overall aim of this work was to provide a set of
designs that can be used prospectively to study DHA
following oral AS administration for all target popula-
tions, which include non-pregnant adults, children and
pregnant women. This was achieved by:
(i) determining appropriate structural PK models
and parameter values for DHA for the target
populations,
(ii) identifying the practical constraints of taking
blood samples from patients,
(iii) determining optimal designs using the informa-
tion above, and
(iv) evaluating the optimal designs.
Methods
Overview of optimal design
In brief, an optimal design for a population PK model (i.
e. a nonlinear mixed-effects model) is the design (i.e. set
of blood sampling times) out of all possible designs that
will maximise the determinant of the population Fisher
information matrix, thereby minimising the standard
errors (i.e. maximising the precision) of the parameter
estimates. This is more specifically a D-optimal design,
but will be referred to as an optimal design throughout
this paper. The method for computing the population
Fisher information matrix using a first-order approxima-
tion of a nonlinear mixed-effects model is given else-
where [6,9]. Software has been developed to determine
optimal designs for nonlinear mixed-effects models [10],
where the user specifies the structural PK model, the
values of the PK parameters, the between-subject varia-
bility of the PK parameters, the residual variability and
an initial sampling scheme. Several models can be
entered simultaneously (competing models), and restric-
tions on potential sampling times can be made to
ensure that the final optimal sampling times are within
the constraints of the study. After this information is
entered, an optimisation algorithm is used to search for
the optimal design, where the design space (i.e. the set
of all possible designs) is limited to the specified restric-
tions on the sampling schedule. The output includes the
optimal sampling times and the expected standard
errors of the model parameter estimates assuming the
optimal design. For technical details see [9].
Determining pharmacokinetic models and parameter
values for the designs
Structural PK models and PK parameter values for DHA
in non-pregnant adults were determined by analysing a
subset of DHA PK data with intensive blood sampling
[11]. The data were derived from studies of non-preg-
nant adult patients with uncomplicated falciparum
malaria attending field clinics on the Thai-Burmese bor-
der (Wang Pha) and western Cambodia (Pailin) who
were given 4 mg/kg of oral AS. Six to twelve venous
blood samples were taken from 32 patients over the first
1 2h o u r sp o s t - d o s i n ga n da s s a y e dt od e t e r m i n eD H A
concentrations. Plasma concentrations of AS and DHA
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chromatography-tandem mass spectrometry after solid
phase extraction [12]. The coefficient of variation for all
quality control samples was less than 5% at all drug
concentrations. Full details of the study have been pub-
lished [11]. For all PK models, it was assumed that AS
was completely metabolised into DHA. This assumption
does not affect the relevance and predictive performance
of the model since only DHA was of interest. The statis-
tical analysis was performed in NONMEM version VI
[13] in conjunction with Wings for NONMEM[14]. In
NONMEM the FOCE (first-order conditional estima-
tion) with INTERACTION method was used.
The results from the analysis of the non-pregnant
adult data were used to define oral clearance and appar-
ent volume of distribution parameters for children and
infants via allometric scaling, which scales these para-
meters by individual body weight relative to a reference
body weight. In addition, maturation on oral clearance
was also incorporated. These calculations were per-
formed since there are few published PK studies of oral
AS in children with intensive blood sampling and very
limited data published on anti-malarial drug concentra-
tions in infants [15]. For technical details of these calcu-
lations see Additional file 1.
The structural PK models and values of their para-
meters for pregnant women were obtained from
McGready et al. [5], which is the only published popula-
tion PK study of oral AS in pregnant women with pre-
senting falciparum malaria.
Identifying sampling constraints
To identify the practical constraints of obtaining blood
samples from malaria patients, a survey was e-mailed to
22 malaria researchers (including clinicians, pharmacol-
ogists and health workers) with extensive experience in
conducting anti-malarial PK studies in Asia and Africa.
JAS wrote the survey, and it was reviewed by NJW and
Prof Richard Price (Menzies School of Health Research,
Darwin, Australia). Information was collected on patient
and logistical factors that restrict the number of blood
samples that can be taken from an individual, possible
times samples could be taken, feasible methods of taking
blood, how many samples could be taken from indivi-
duals within 8 and 24 hours post dosing, the maximum
number of samples that could be taken from an indivi-
dual and the minimum time between consecutive sam-
ples. The latter four items were noted for adults,
children and pregnant women by field setting (hospital
or community patients).
Determination of the optimal designs
Optimal designs for future population PK studies of
DHA in adults, children and pregnant women were
determined using POPT[16]. The designs were based on
the determined structural PK models, parameter values,
likely values of covariates (i.e. age and/or weight) and
key constraints identified in the questionnaire.
For all designs, competing models were entered into
POPT to incorporate uncertainty in the structural PK
models and/or parameter values. For the structural PK
models, this was done by defining each plausible
model in POPT. Then for each structural PK model
defined, the PK parameter values were set to the popu-
lation mean estimates and the lower and upper bounds
of their respective 95% confidence intervals (thus three
sets of PK parameter values were considered for each
structural model). Furthermore, 95% weight was allo-
cated to the models with the PK parameters set to the
population estimates. The designs were then deter-
mined by optimising over all competing models simul-
taneously. This method for robust design has been
used previously [17] and has been shown to be as
effective as ED designs but without the computational
burden [18].
To provide flexibility for taking blood samples in the
field, sampling windows were computed in POPT for
each optimal sampling time. A sampling window is a
time interval containing the optimal sampling time,
where any blood sample taken within the interval
ensures minimal impact on the precision of the esti-
mated parameters. POPT determines the windows via a
three-stage sampling procedure where samples are gen-
erated randomly and those that achieve the necessary
level of efficiency are accepted. For further details see
[16]. For the determined designs, the windows were
constructed such that there would be a minimal increase
in the standard errors as defined by a 20% reduction in
the overall statistical efficiency relative to the optimal
sampling times.
Evaluation of the optimal designs
The robustness of the optimal designs was evaluated by
a simulation-estimation procedure that was automated
in NONMEM. So for each optimal design:
1. 100 datasets were simulated, where each dataset
consisted of virtual individuals that were randomly
selected from a hypothetical population that
matched the characteristics (i.e. ages and/or weights)
of the target population (e.g. non-pregnant adults,
children or pregnant women).
2. Individual DHA concentrations were simulated at
the optimal sampling times from a respective popu-
lation PK model.
3. Each simulated dataset was analysed with NON-
MEM using the FOCE with INTERACTION
method.
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tion of the estimates from the 100 analyses was
computed. These standard deviations of the esti-
mated parameters can be regarded as empirical stan-
dard errors. The empirical standard errors were then
expressed as percent relative standard errors (%
RSEs), where the %RSE is given by 100 multiplied by
the empirical standard error divided by the median
parameter estimate from the 100 analyses. The
empirical %RSEs were compared with the expected
%RSEs from POPT.
For the simulation of the virtual individuals (step 1),
non-pregnant adult weights were simulated based on
the non-pregnant adult PK DHA data from the Thai-
Burmese border and Western Cambodia [11]. For
designs with children, ages and weights were simulated
from a linear model based on data from Simpson et al.
[19]. Weights for pregnant women were derived from
the weight distribution reported in McGready et al. [5].
Results
Pharmacokinetic models and parameter values for the
designs
The left graph of Figure 1 displays the DHA PK data
reported in non-pregnant adult patients (n = 32) [11].
Table 1 displays the results from analysing this data and
hence the PK models and parameter values that were
used for determining the optimal designs for non-preg-
nant adults. From the analysis, four (competing)
structural PK models were selected for determining
optimal designs for non-pregnant adults: Bateman with-
out a lag-time, Bateman with a lag-time, Dost without a
lag-time and Dost with a lag-time. The mathematical
details of these models are given in Additional file 1.
Table 1 also displays the parameter values of the Bate-
man model for pregnant women proposed by McGready
et al. [5], and the right graph of Figure 1 shows the cor-
responding population PK profile. The authors did not
estimate the between-subject variability (BSV) of the
absorption rate constant (ka) and the residual stan-
dard deviation (s) was not reported, so the values of
these parameters were set to those of the non-pregnant
adults for the determination of the optimal designs.
PK parameters for children were based on results
from the Bateman models for the non-pregnant adults
in Table 1 and applying maturation to CL/F and allo-
metric scaling to CL/F and V/F.T h eD o s tm o d e lw a s
not considered since it is a simpler version of the Bate-
man model where only V/F can be scaled. The age/
weight combinations required for the scaling and
maturation were based on a linear model using data
from [19] (more details of the age/weight combinations
for the designs are given below and in Additional file 1,
Figure S2).
Sampling constraints
Sixteen of the 22 malaria researchers contacted (73%)
responded to the questionnaire regarding blood sam-
pling of malaria patients. The reported number of blood
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Figure 1 Population pharmacokinetic profiles of DHA for pregnant and non-pregnant adults. The left graph displays the DHA
concentrations from the 32 non-pregnant adults reported in [11] and the population pharmacokinetic profiles that were estimated from this
data. The right graph shows the population pharmacokinetic profile for pregnant women reported in [5].
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settings within 8 hours post dosing ranged from one to
six for adults (pregnant and non-pregnant) and one to
four for children. For all patient groups, responses for
the minimum time between blood samples (for any anti-
malarial drug) ranged from 15 minutes to 24 hours.
Given these constraints, it was decided that adults
should have four blood samples taken whereas children
should have three, where consecutive samples from an
individual patient would be at least 15 minutes apart.
Three to four samples per patient would allow a single
sampling schedule (at least for the adults), which is
appealing for clinical implementation, and would require
only a moderate number of patients (i.e. 50-100) to
achieve acceptable parameter precision. It was also felt
that a minimum of three samples per patient would pro-
vide means for distinguishing between residual and
between-subject variability, which have been reported to
be large for DHA [19].
Optimal designs
Using the PK models and parameter values given in
Table 1 and the sampling constraints described above,
three sets of designs were determined in POPT:
(i) non-pregnant adults only,
(ii) non-pregnant adults and children, and
(iii) pregnant women only.
Separate designs for the non-pregnant adults and
pregnant women were considered reasonable since
adequate sampling could be done in both groups and
there was evidence for substantial differences in their
population PK profiles. Children were included in a
design with adults since only minimal sampling could
be performed in children, and consisted of four
age groups: <2 years, 2-10 years, 11-20 years and >20
years (the age groups were determined from the
questionnaire).
Table 1 Population pharmacokinetic models and parameter values for the non-pregnant adults and pregnant women
designs
Non-pregnant adults Pregnant women
♭,♮
Model &Parameter*
,§ Estimate
† (95% CI)
◇ Estimate
‡ (95% CI)
◇ Estimate
† (95% CI)
◇
Bateman model
ka (/h) 0.82 (0.76, 0.87) 0.89 (0.81, 0.97) 1.19 (0.78, 1.60)
CL/F (L/h) 47.5 (44.6, 50.4) 48.8 (42.3, 55.3) 88.5 (60, 117)
V/F (L) 32.1 (24.6, 39.6) 44.4 (30.2, 58.6) 232 (57.0, 406)
tlag (h) 0.21 (fixed) n/a 0.42 (0.34, 0.50)
ka 26.7 11.4 not reported
ΩCL/F 29.4 26.8 47.0
ΩV/F 81.9 64.7 154
tlag 10.0 n/a not reported
ΩCL/F,V/F 0.58 0.75 not reported
ka,tlag 0.19 n/a not reported
s 0.41 0.55 not reported
Dost model
k (/h) 0.99 (0.91, 1.1) 0.95 (0.86, 1.03)
V/F (L) 46.3 (37.6, 55.0) 51.3 (41.2, 61.4)
tlag (h) 0.21 (fixed) n/a
Ωk 22.0 20.8
ΩV/F 48.2 42.2
tlag 11.4 n/a
Ωk,V/F -0.79 -0.81
s 0.47 0.57
*The Ω’s represent between-subject variances and covariances, expressed as the percent coefficient of variation (%CV, approximated by the square root of the
variance estimate multiplied by 100) and correlation coefficients, respectively
§The s’s represent residual standard deviations (proportional)
♭Taken from McGready et al.[ 5 ]
♮Reported CL/F (L/kg/h) and V/F (L/kg) multiplied by median weight (50 kg)
†Lag-time included
‡Lag-time not included
◇Upper and lower bounds of CIs were considered for the PK parameters only
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sidered logistically feasible and a necessary minimum for
parameter estimation. For all designs it was specified in
POPT that the optimal sampling times had to be at
least 15 minutes apart over a dosing interval of 24
hours. Table 2 displays the optimal sampling times and
sampling windows from POPT for each design. A gra-
phical display of the optimal times and windows is pro-
vided in Additional file 1, Figure S1.
Evaluation of the optimal designs
Tables 3 and 4 display the results from the simulation-esti-
mation procedure using the Bateman and Dost models for
analysis (respectively) along with the expected %RSEs of
the model parameters from POPT assuming the optimal
sampling times. For all designs, data were simulated from
and analysed with the Bateman model with a lag-time.
This was done since this model provided the best fit to the
non-pregnant adult data and was reported in McGready et
al. [5]. In addition, the Dost model was used to analyse
the simulated data from the non-pregnant adult design.
For the simulation step of the non-pregnant adult only
and non-pregnant adult and children designs, parameter
values were set to the population estimates from the non-
pregnant adult analysis (allometric scaling and maturation
was used for the latter design). For the simulation step of
the pregnant women designs, the parameter values were
set to those identified in McGready et al. [5] with the BSV
of ka set to that of the non-pregnant adults and the BSV
of V/F reduced to 1 (see Tables 3 and 4 for details).
Table 2 Optimal sampling times and sampling windows from POPT for each design
Design Optimal times
(sampling windows)
Non-pregnant adults*
(n = 60)
20 min
(17 to 29 min)
35 min
(30 to 57 min)
3.0 h
(2.5 to 3.7 h)
6.2 h
(5.8 to 6.6 h)
Non-pregnant adults and children*
<2 y (n = 10):
19 min
(16 to 28 min)
2.3 h
(2.0 to 2.8 h)
5.8 h
(5.5 to 6.1 h)
2-10 y (n = 10): 19 min
(16 to 26 min)
34 min
(31 min to 1.0 h)
5.76 h
(5.5 to 6.2 h)
11-20 y (n = 10): 20 min
(17 to 29 min)
2.2 h
(2.1 to 3.0 h)
6.1 h
(5.6 to 6.5 h)
>20 y (n = 30): 20 min
(18 to 27 min)
2.5 h
(2.2 to 2.7 h)
2.8 h
(2.7 to 3.4 h)
6.1 h
(5.9 to 6.6 h)
Pregnant women*
,†,‡
(n = 60)
43 min
(35 to 59 min)
3.3 h
(1.2 to 3.4 h)
3.5 h
(3.4 to 4.9 h)
7.4 h
(6.0 to 8.0 h)
*For structural models with a lag-time, the lag-time parameter and its BSV were specified in POPT to not be estimated
†The BSV of ka was set to that of the non-pregnant adults and the BSV of V/F was reduced to 1
‡Competing values of the BSV of V/F were set to 0.67 (derived from the results of the non-compartmental analysis in [5]) and 2.37 (the reported BSV from the
population PK analysis in [5])
Table 3 Expected and empirical percent relative standard errors (%RSEs) for the Bateman model assuming the optimal
designs
ka CL/FV /Ft lag ka ΩCL/F ΩV/F s
Non-pregnant adults
Optimal design
POPT* 5.44 3.73 10.15 - 45.5 22.2 17.5 4.98
Simulation-estimation
†,‡ 10.7 5.99 17.3 6.86 52.9 30.7 21.6 7.87
Non-pregnant adults and children
Optimal design
POPT* 5.14 3.81 10.4 - 42.5 23.6 19.0 5.83
Simulation-estimation
†,‡ 8.97 5.63 22.7 9.88 55.2 37.4 29.2 8.52
Pregnant women
Optimal design
POPT* 8.22 4.76 10.5 - - 15.9 14.7 4.20
Simulation-estimation
†,# 14.7 8.28 17.5 8.67 - 27.0 25.8 7.33
*Expected %RSEs
†Empirical %RSEs
‡tlag fixed
#tlag and ka fixed
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parameters, but this resulted in NONMEM being unsuc-
cessful with minimising the objective function for rea-
sons other than rounding errors in many of the runs.
To improve this, the BSV of tlag was fixed to the value it
was simulated at for all designs, and for the pregnant
women design the BSV of ka was also fixed to the value
it was simulated at. After these modifications, all models
from the non-pregnant adult only and non-pregnant
adult and children designs converged, and 96 of the
models converged for the pregnant women design. The
empirical %RSEs from all designs were consistently
higher than the expected %RSEs from POPT, but still
acceptable (<25% for the PK parameters and ≤55% for
the BSVs). In addition, for the non-pregnant adults and
children design, the maturation of oral clearance
assumption was assessed by performing two additional
simulation-estimations, varying the value of kmat (see
Additional file 1 for an explanation of this parameter).
Both of these simulation-estimations yielded similar
results to those presented in Table 3.
To highlight how substantial the decrease in parameter
precision can be by taking very few samples per patient,
naïve designs, that is less intensive sampling schedules based
on sampling constraints consistent with responses from the
questionnaire and passing consideration of PK profiles, were
evaluated via the simulation-estimation process described in
the Methods section for all patient populations. See Addi-
tional file 1 for details of the naïve designs and the results
from the evaluation (Additional file 1, Table S1).
Discussion
This work determined optimal study designs for future
population PK studies of DHA following oral AS for all
k e yt a r g e tp o p u l a t i o n sw h e r eo n l yas m a l ln u m b e ro f
blood samples can be taken. The proposed sampling
schedules resulted in acceptable precision of the PK and
between-subject variance parameters.
The optimal designs were determined using popula-
tion PK models from Asian populations, however the
resulting sampling schedules should also be applicable
to African populations. Models from Asian populations
were used since knowledge of the population pharmaco-
kinetics of DHA following oral AS in African patients
with presenting falciparum malaria is scant. Stepniewska
et al. performed a population PK study of AS and DHA
in African children with uncomplicated malaria [20],
however the data were very sparse (one sample per
child for a given dose) and between-subject variability
was reported for only one PK parameter (CL/F). A very
recent study reported the population pharmacokinetics
of DHA following oral AS in pregnant and non-preg-
nant women in Africa [21], but these women were
asymptomatic and displayed low-grade parasitaemia.
Also, the authors noted that their results were compar-
able to McGready et al. [21]. Therefore it was decided
to not use the results from [20] or [21] and instead base
the designs on an analysis of the rich non-pregnant
a d u l td a t af r o m[ 1 1 ]a n dt h er e p o r t e dm o d e lf o rp r e g -
nant women in [5]. Though Asian and African popula-
tions may differ in factors that affect the PK (e.g. in
terms of weight and Cytochrome P450 enzyme poly-
morphism), uncertainty was incorporated into the PK
parameters to ensure the designs were robust to some
alternative population PK profiles. To check this, the
optimal designs were evaluated post hoc in POPT
assuming PK profiles from individuals weighing 70 kg
(via allometric scaling of the Asian CL/F and V/F para-
meters) and yielded similar expected precision to that
shown in the Results section. Furthermore, results from
[21] and published non-compartmental analyses of DHA
following oral AS in African populations [22-24] were
examined. The displayed data from [22] appeared to clo-
sely follow the population PK profile for children used
for the designs, however [21], [23] and [24] showed
somewhat different profiles than those used for the non-
pregnant adults and pregnant women designs. Using the
displayed data in [23] and [24], Bateman model para-
meters were approximated via nonlinear regression, and
a Bateman model with zero-order absorption was
approximated from the results in [21]. The optimal
designs were again evaluated post hoc in POPT assum-
ing these approximated profiles (the BSVs from the
Asian populations were used for models approximated
from [23] and [24]). For the models approximated from
[23] and [24], the optimal designs gave acceptable preci-
sion for CL/F and V/F (and their BSVs), but required ka
and/or its BSV to be fixed. In the case of the approxi-
mated zero-order absorption model, the BSV of V/F was
required to be fixed for the pregnant women design.
Therefore when studying African populations it is
recommended to vary sampling within the windows,
especially within the absorption phase, to gain more
knowledge of the population PK profiles for this group.
In particular, it is recommended to take some samples
later in the windows, as results from [23,24] and [21]
Table 4 Expected and empirical percent relative standard
errors (%RSEs) for the Dost model assuming the optimal
designs
kV /Ft lag Ωk ΩV/F s
Non-pregnant adults
Optimal design
POPT* 2.32 5.06 - 16.7 17.3 4.31
Simulation-estimation
†‡ 4.33 8.05 8.77 24.7 19.4 7.46
*Expected %RSEs
†Empirical %RSEs
‡tlag fixed
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mum concentration. As more population PK studies are
performed in Africans, the optimal designs can be
updated to cater for any observed differences. Addition-
ally, it is also recommended to vary sampling within the
windows for Asian populations, as this may provide
more information about other plausible structural PK
models (e.g. a two-compartment model), increased flex-
ibility for parameter estimation and a safeguard against
the possibility that the structural models and parameter
values the designs were based on were incorrect.
The pregnant women design was based on models
obtained from McGready et al.[ 5 ] ,w h i c hw a st h eo n l y
published work found on the population pharmacokinetics
of DHA in pregnant women with presenting falciparum
malaria. The BSV for V/F was extremely large, which is
likely due to V/F soaking up the between-subject variabil-
ity of ka, which was not estimated. To account for at least
some between-subject variability of ka in the design, the
BSV of ka was set to that of the non-pregnant adults. To
compensate for the inclusion of the BSV for ka, the popu-
lation value for the BSV of V/F was reduced. It is therefore
possible that alternative sets of PK parameter values exist
for this group, so as previously noted sampling should be
varied within the windows and as more PK data become
available from pregnant women the optimal design will be
re-evaluated. In addition, if the investigator expects to use
an analytical method for measuring DHA concentrations
that is less sensitive than that used in [11], it is recom-
mended to take the last blood sample in pregnant women
earlier within the sampling window to ensure that the con-
centration is above the lower limit of quantification. This
should also be done for children if a less sensitive analyti-
cal method is used.
For all designs, the empirical %RSEs were consistently
higher than the expected %RSEs from POPT. This
observed difference may have been due to the way covari-
ates (i.e. weight and age) were dealt with in POPT and the
simulation-estimation procedure. In POPT, likely values
for age and weight were assumed (i.e. weight for the adult
designs and a range of age/weight combinations for each
age group of the design with children). However, for the
simulation-estimations, distributions were assumed for age
and weight based on these likely values. Though this dif-
ference in procedures may have contributed to the consis-
tently higher empirical %RSEs, the empirical %RSEs were
still acceptable for both the PK parameters (<25%) and
BSVs (≤55%). Furthermore, the %RSEs from the popula-
tion Fisher Information matrix are lower bounds, so it is
not surprising that the empirical %RSEs were larger.
Therefore the derived optimal designs should be robust to
plausible values of age and weight, and as more informa-
tion is collected on the effect of these covariates on the PK
parameters the designs can be re-evaluated.
The optimal sampling schedules proposed in this work
were based on the key constraints of three to four blood
samples per patient, a minimum of 15 minutes between
consecutive samples and a sample size of 60 individuals.
Thus they are the optimal sampling times assuming
these key constraints. However, it is recommended to
take additional blood samples, if at all possible, and if
convenient within the sampling windows. Additional
samples will provide even more information for the esti-
mation of the model parameters and may assist with the
exploration of other plausible structural PK models and/
or parameter values.
Conclusions
The use of optimal design methodology provided an
analytical yet flexible framework to determine robust
and efficient designs for future population PK studies of
DHA following oral AS for all target populations,
including pregnant women and children.
Current dosing recommendations for oral AS provide
a resistance selection opportunity in patients with low
drug concentrations and high parasite burdens, which
are often children and pregnant women [25]. More
population PK studies that are optimally designed, and
using pharmacokinetic-pharmacodynamic (PK-PD) mod-
els are required to determine dosing regimens that
achieve effective drug concentrations in all malaria
patients [26,27]. The optimal designs proposed in this
paper can be used in future studies to obtain precise PK
parameter estimates under heavy sampling constraints,
and can be considered a prototype for an iterative open
access design support tool to help investigators studying
anti-malarial efficacy and pharmacology in field studies.
These will be provided by the Clinical Pharmacology
module of the Worldwide Antimalarial Resistance
Network [26].
Additional material
Additional file 1: This file explains the mathematical details of
applying allometric scaling and maturation to PK parameters, the
Bateman model and the Dost model. The results from the evaluation
of the naïve designs are also displayed [28-31].
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